IntegraMed America, Inc. (NASDAQ: INMD) ("IntegraMed" or "the Company"),
a leader in developing, marketing and managing specialty healthcare
facilities in the fertility
and vein
care markets, announced today that it has entered into a definitive
agreement to be acquired by affiliates formed by Sagard Capital
Partners, L.P. ("Sagard Capital"), an investment fund and IntegraMed
shareholder, for $14.05 per share in cash, or a total equity purchase
price of $169.5 million. The consideration represents a 24% premium to
IntegraMed's closing stock price of $11.34 on June 8, 2012, the last
trading day prior to today's announcement, and a 46% premium to
IntegraMed's average daily closing price over the past year.
Jay Higham, Chairman, CEO and President of IntegraMed, commented, "This
transaction delivers on two of our key objectives, as we have secured a
premium to IntegraMed's share price and a long-term partnership with a
respected investor. With Sagard, we will have the additional financial
flexibility to continue investing in the growth of our business. Sagard
is a long-term investor, and this transaction demonstrates their
confidence in the Company's fundamental business operations and growth
prospects. Furthermore, we believe that Sagard's principals respect and
value the unique team of physicians, clinic staff and management that
are the foundation of IntegraMed's success."